(Q52908251)

English

Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors.

scientific article published on 20 October 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/26486517

Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. (English)

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/26486517

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486517%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

author name string

Elizabeth Fox

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486517%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Brigitte C Widemann

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486517%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Devang Pastakia

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486517%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Clara C Chen

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486517%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Sherry X Yang

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486517%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Diane Cole

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486517%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

publication date

20 October 2015

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/26486517

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486517%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

76

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486517%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486517%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1273-1283

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26486517%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

https://scigraph.springernature.com/pub.10.1007/s00280-015-2845-1

0 references

The multidrug resistance (mdr1) gene product functions as an ATP channel

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

Can multidrug resistance mechanisms be modified?

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

Pharmacokinetics of single ascending doses of the P-glycoprotein inhibitor tariquidar in healthy subjects

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

Diagnosis and reversal of multidrug resistance in paediatric cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

Clinical pharmacokinetics of docetaxel.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

Expression of a multidrug-resistance gene in human tumors and tissues

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

Strategies for reversing drug resistance

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

Multidrug resistance in cancer: role of ATP-dependent transporters

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

Resistance mechanisms associated with altered intracellular distribution of anticancer agents.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

Coadministration of P-glycoprotein modulators on loperamide pharmacokinetics and brain distribution.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

Specific inhibitors of the breast cancer resistance protein (BCRP).

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

Small and Innovative Molecules as New Strategy to Revert MDR

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2845-1

21 January 2018

P-glycoprotein and multidrug resistance in cancer chemotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26486517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical significance of P-glycoprotein in multidrug resistance malignancies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26486517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26486517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918

1 reference

https://pubmed.ncbi.nlm.nih.gov/26486517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833

1 reference

https://pubmed.ncbi.nlm.nih.gov/26486517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26486517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26486517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26486517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26486517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interactions of the multidrug resistance modulators tariquidar and elacridar and their analogues with P-glycoprotein

1 reference

https://pubmed.ncbi.nlm.nih.gov/26486517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52908251&oldid=2144100209"